Black Cohosh for Hot Flashes: What the Trials Actually Found

Black cohosh (Actaea racemosa, formerly Cimicifuga racemosa) is a woodland plant native to eastern North America, used by Indigenous peoples for a range of conditions and adopted into European herbal medicine in the nineteenth century. Today it is the most widely sold botanical supplement for menopause symptoms in the United States and much of Europe, usually standardized to triterpene glycoside content and sold under brand names like Remifemin.

Its popularity has an obvious origin: the Women's Health Initiative. When the WHI results were published in 2002 and widely reported as showing serious risk from hormone therapy, millions of women stopped HRT within months. Sales of botanical alternatives rose sharply, and black cohosh — already on shelves, already familiar — captured much of that demand. The subsequent reanalysis of the WHI data was considerably more nuanced than the initial coverage suggested, which is worth understanding if you're weighing your options; that story is covered in [HRT and breast cancer risk: what the WHI really found](/blog/hrt-and-breast-cancer-risk-what-the-whi-data-actually-shows).

Early interest was mechanistically plausible. Researchers initially believed black cohosh had phytoestrogenic activity — that it bound estrogen receptors and provided a mild estrogen-like effect. That hypothesis has since been largely abandoned; current laboratory work does not support meaningful estrogen receptor binding. Alternative proposed mechanisms involve serotonergic or dopaminergic pathways, but none has been established.

Which leaves the question that matters: mechanism aside, does it work?

It found no benefit over placebo, and it is the most rigorous test the supplement has faced. The Herbal Alternatives for Menopause Trial (HALT), led by Katherine Newton and published in Annals of Internal Medicine in 2006, was a 12-month randomized, double-blind, placebo-controlled study in 351 women aged 45 to 55. Participants were assigned to one of five arms: black cohosh alone; a multi-botanical supplement containing black cohosh and other herbs; that multi-botanical plus dietary counselling to increase soy intake; hormone therapy; or placebo.

The results were unambiguous. Frequency and severity of hot flashes and night sweats declined by roughly 30% over 12 months regardless of which supplement arm women were in — including placebo. Of the five interventions, only hormone therapy separated from placebo, reducing symptoms by an average of about four per day.

The 30% placebo response is the most important number in that paragraph, and it explains a great deal about the supplement industry. Vasomotor symptoms fluctuate naturally, women typically seek treatment when symptoms are at their worst, and expectation effects in menopause trials are unusually strong. Take anything at your peak of misery and you will very likely feel better in three months. That improvement is real. It just isn't caused by the pill.

A Cochrane systematic review by Leach and Moore in 2012 pooled 16 trials covering 2,027 women and concluded there was insufficient evidence to support black cohosh for menopausal symptoms, noting that the trials were generally small and methodologically inconsistent. Later reviews have not changed that verdict.

Mostly, with one uncommon but serious exception. The common side effects are mild — gastrointestinal upset, headache, rash, and occasional dizziness — and most women who take it report tolerating it well.

The concern is hepatotoxicity. Case reports of liver injury associated with black cohosh, ranging from raised liver enzymes to acute liver failure requiring transplant, prompted regulatory review in several countries. The European Medicines Agency and health authorities in the UK, Australia, and Canada now require products to carry a liver warning. Causation in individual cases has been difficult to establish definitively — supplement products are variably standardized and often adulterated with other species — but the regulatory position is that the signal is credible enough to warn about.

What that means practically: stop and seek medical attention if you develop yellowing of the skin or eyes, dark urine, unusual fatigue, or persistent right-sided upper abdominal pain. Avoid black cohosh entirely if you have existing liver disease, and be cautious combining it with other supplements or medications that stress the liver.

There are two other groups who should be careful. Women with a history of breast cancer are usually advised to discuss any menopause supplement with their oncology team — the phytoestrogen hypothesis has been weakened, but the trial data in this population remains limited. And because supplement manufacturing is loosely regulated, product identity is a real issue: analyses have repeatedly found bottles labelled Actaea racemosa containing cheaper Asian Actaea species instead. If you take it, choose a brand with third-party verification such as USP.

Several, and they range from prescription medications to behavioural approaches with genuine trial support.

The strongest new category is the neurokinin receptor antagonists. These work on the KNDy neurons in the hypothalamus that regulate body temperature — the actual mechanism of a hot flash — rather than on hormones at all. Fezolinetant (Veozah) and elinzanetant (Lynkuet) both showed significant reductions in hot flash frequency and severity against placebo in phase 3 trials. They require a prescription and, for fezolinetant, liver monitoring. The comparison is laid out in [Lynkuet vs Veozah](/blog/lynkuet-vs-veozah-nonhormonal-hot-flash-pills-compared).

Cognitive behavioural therapy is recommended by NICE specifically for vasomotor symptoms. It doesn't reduce the physiological flush much, but it substantially reduces how bothersome the flushes are and improves sleep and mood alongside — a distinction that sounds like a downgrade until you've lived it. Details in [CBT for menopause](/blog/cbt-for-menopause-nice-recommended-nonhormonal-treatment).

Clinical hypnotherapy has surprisingly good trial data, with randomized studies showing reductions in hot flash frequency substantially greater than placebo — better, in fact, than most supplements manage. See [hypnotherapy for hot flashes](/blog/hypnotherapy-for-hot-flashes-does-it-actually-work).

Certain antidepressants — low-dose SSRIs and SNRIs such as paroxetine, venlafaxine, and escitalopram — reduce hot flashes at doses below those used for depression, and paroxetine mesylate is FDA-approved for this specific use. Gabapentin helps particularly with night-time symptoms. Both are prescription options worth raising with a clinician.

And if hormone therapy has been ruled out in your mind based on headlines rather than a conversation, it may be worth revisiting. For many women within ten years of their final period, the risk-benefit calculation is more favourable than the 2002 coverage implied.

Not necessarily — but it's worth understanding what you're likely experiencing, and what it's costing you.

If you started black cohosh and your hot flashes improved, that improvement is real. You are not imagining it. But the HALT trial tells us the same improvement occurred in women taking identical-looking placebo capsules, which means the pill is probably not the cause. Some of it is natural symptom fluctuation, some is regression to the mean, and some is the genuine physiological effect of expectation — placebo responses involve measurable changes, not just reported ones.

The honest cost-benefit runs like this. Black cohosh is inexpensive, generally well tolerated, and unlikely to harm most people. If you're taking it, feeling better, and not troubled by the liver signal, continuing is a defensible choice. The cost is not really the money.

The real cost is delay. Perimenopause and early menopause are a window, not a permanent state, and some decisions are time-sensitive. The bone loss that peaks around the final menstrual period isn't recoverable later. If hot flashes are wrecking your sleep, months spent cycling through supplements are months of accumulated sleep debt with its own consequences for mood, cognition, and cardiovascular risk. Women routinely spend two or three years working through the supplement aisle before having a proper conversation about treatment — and arrive at that conversation with the window narrowed.

A reasonable approach: give any single intervention a defined trial — eight to twelve weeks — with some way of tracking symptoms rather than relying on memory. If it hasn't clearly helped by then, stop and move on rather than adding another bottle alongside it. And bring the list of what you've tried to a clinician who takes menopause seriously. 'I've tried black cohosh, magnesium, and evening primrose oil over the past two years and I'm still not sleeping' is a much more actionable sentence than 'I'm having hot flashes.'